Evidence map›Paper›PMID 36856421›Full record

ArticleAntimicrobial agents and chemotherapy2023

Novel Transmission-Blocking Antimalarials Identified by High-Throughput Screening of Plasmodium berghei Ookluc.

Juliana Calit, Jessica E Araújo, Bingbing Deng, Kazutoyo Miura, Xiomara A Gaitán, Maisa da Silva Araújo, Jansen F Medeiros, Carole A Long, Anton Simeonov, Richard T Eastman and 1 more

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Juliana CalitDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil.
Jessica E AraújoPlataforma de Produção e Infecção de Vetores da Malária-PIVEM, Laboratório de Entomologia, Fundação Oswaldo Cruz-Fiocruz Rondônia, Porto Velho, Rondônia, Brazil.
Bingbing DengLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Xiomara A GaitánDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil.
Maisa da Silva AraújoPlataforma de Produção e Infecção de Vetores da Malária-PIVEM, Laboratório de Entomologia, Fundação Oswaldo Cruz-Fiocruz Rondônia, Porto Velho, Rondônia, Brazil.
Jansen F MedeirosPlataforma de Produção e Infecção de Vetores da Malária-PIVEM, Laboratório de Entomologia, Fundação Oswaldo Cruz-Fiocruz Rondônia, Porto Velho, Rondônia, Brazil.
Carole A LongLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Anton SimeonovDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0002-4523-9977
Richard T EastmanDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0003-3580-380X
Daniel Y BargieriDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil.ORCID 0000-0003-2564-3742
National Institutes of Health · USUniversidade de São Paulo · BRUniversidade Federal de Rondônia · BRFundação Oswaldo Cruz · BR

Funding

Host Immune Responses to Antigens of Malaria ParasitesZIAAI001020 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LONG, CAROLE · 2009 to 2025
$13.6M
6 · The paper itself

Abstract

Safe and effective malaria transmission-blocking chemotherapeutics would allow a community-level approach to malaria control and eradication efforts by targeting the mosquito sexual stage of the parasite life cycle. However, only a single drug, primaquine, is currently approved for use in reducing transmission, and drug toxicity limits its widespread implementation. To address this limitation in antimalarial chemotherapeutics, we used a recently developed transgenic Plasmodium berghei line, Ookluc, to perform a series of high-throughput

Indexed as

AntimalarialsCulicidaeMalariaMalaria, FalciparumMalaria, VivaxAnimalsHigh-Throughput Screening AssaysHumansPlasmodium bergheiPlasmodium falciparumPrimaquineAntimalarialsPrimaquinecompound screenmalariatransmission blocking

Identifiers

PMID36856421
PMCPMC10112123
OpenAlexW4322719670

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.